Skip to main content

Table 1 Background data for patients with rheumatoid arthritis (RA)

From: Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates

 

Bisphosphonate group

(n= 42)

Bisphosphonate + statin group

(n= 35)

P-value

(Student's t-test)

Age, years

66.4 ± 6.2 (49.3, 77.6)

65.3 ± 6.8 (52, 76.8)

0.463

Sex

   

Male

2

0

 

Female

40

35

 

59 >

3

8

 

60-69

24

17

 

70 <

13

10

 

Disease duration, years

24.9 ± 10.6 (6.1, 54.3)

20.8 ± 8.9 (5.9, 38.)

0.083

Bisphosphonates

   

Alendronate

31

26

 

Etidronate

4

5

 

Risedronate

7

4

 

Administered

   

> 4 years

29

22

 

1 to 4 years

13

13

 

Prednisolone, mg

2.4 ± 2.0 (0, 6.0)

2.8 ± 2.1 (0, 7.0)

0.355

+

30

28

 

-

12

7

 

Methotrexate, mg

5.2 ± 3.2 (0, 10)

4.1 ± 3.1 (0, 10)

0.140

+

34

25

 

-

8

10

 

Vitamin D 3 , μg

0.5

0.5

 

+

7

3

 

-

35

32

 
  1. Results are presented as mean ± SD (range) or number of patients. P-values are for comparisons between the two treatment groups.